Galderma Q3 Sales Climb; Raises FY26 Sales Growth Outlook
Galderma reported third-quarter sales of $1.63 billion and raised its sales growth outlook while confirming its FY26 core EBITDA margin view.
WASHINGTON (dpa-AFX) - Galderma Group AG (GALD.SW, GALDY), a Swiss pharmaceutical company, reported Thursday strong growth in third-quarter sales, with broad-based double-digit growth across geographies and product categories.In the quarter, total Group sales climbed 26.6 percent to $1.63 billion f…